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Introduction
The study of costs associated with antimicrobials treat-
ment of patients with bloodstream infection (BSI) are
important to sustain implementation of preventive mea-
sures and increase patient safety.
Objectives
Compare the direct cost of treatment of patients with
BSI caused by methicillin-resistant and susceptible Sta-
phylococcus aureus (MRSA and MSSA).
Methods
A retrospective cohort study performed in an intensive
care unit of a large hospital in Belo Horizonte. The popu-
lation is comprised of patients with Staphylococcus aur-
eus BSI from 2007 to 2011. Data were obtained through
patients’ medical records, hospital infection control com-
mittee and hospital’s finance department. Therapy costs
were grouped according to the type of treatment
received: empirical (before the culture test result) or
directed (according to the BSI causing agent). Descriptive
and univariate analysis were performed. The hospital’s
Ethics Committee approved the project.
Results
62 patients were included, 31 in each group (MRSA and
MSSA). For empirical treatment, due to the larger doses
of meropenem used in MRSA patients at this stage,
patients with MRSA had a statistically significant
(p<0.005) larger cost ($1110.22) when compared to
MSSA ones ($ 506.34). For directed and total treatment,
difference between groups was not significant (directed
treatment: MRSA $304.74 and MSSA $432.96; total treat-
ment: MRSA $1061,01 and MSSA $829.40). This
occurred due to the larger oxacillin dosages administered
in patients with MSSA when compared with the treat-
ment of vancomycin for patients with MRSA However,
for both groups together, the costs of directed treatment
($327.57) were smaller than the costs of empirical treat-
ment ($551.43) (p=0.000) showing that antimicrobial de-
escalation reduced the directed costs.
Conclusion
Bacterial resistance may influence the costs of antimicro-
bial treatment. The treatment targeting favored a rational
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